LeonaBio, Inc. — Form SCHEDULE 13D
Filed August 31, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
▲ Likely positive
significance 78/100
What the filing says
Sermonix Pharmaceuticals, Inc. (Delaware corporation, CIK 0001655566) filed a Schedule 13D on 2026-08-31 regarding beneficial ownership in LeonaBio, Inc. (public market value ~$9.9M, CIK 0001620463). The filing includes a joint filing agreement and powers of attorney from Sermonix and David Portman, but the specific ownership percentage, share count, dollar amount, and nature of the acquisition are not disclosed in the metadata provided—the actual Schedule 13D document text is not included in this filing extract.
Why this rating
Schedule 13D signals material ownership stake (≥5%) in micro-cap $9.9M company; likely transformational for LeonaBio. Missing specifics prevent higher score.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $7.92 ▲ 0.00% | at our read · unknown $7.92 | +10 min · unknown $7.92 ▲ 0.00% | +30 min · unknown $7.92 ▲ 0.00% | +1 hr · unknown $7.92 ▲ 0.00% | +4 hrs · unknown $7.92 ▲ 0.00% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.